Treatment of generalized periodontitis in patients with metabolic syndrome

Objective. The purpose of this work is to assess the effectiveness of complex treatment of generalized periodontitis affected by metabolic syndrome using drugs that increase the sensitivity of peripheral tissues to insulin. Materials and Methods. The study enrolled 96 male patients with generalized chronic periodontitis affected by metabolic syndrome. The standard treatment regimen of generalized periodontitis in the main study group included drugs that improve insulin sensitivity, namely, metformin and mexidol. Periodontal indices were assesses during the clinical trial. ELISA-based saliva testing was used to determine the level of interleukins IL-1fi, IL-4, IL-6, TNF-a and secretory IgA (SIgA). Periodontal indices were assesses during the clinical trial. ELISA-based saliva testing was used to determine the level of interleukins IL-1fi, IL-4, IL-6, TNF-a and secretory IgA (SIgA). Microcirculation status was analyzed on the basis of reoparodontography results. Results. It was found out that the suggested treatment modality was accompanied by a significant decrease in the tested clinical periodontal indexes, levels of proinflammatory cytokines, increase in the level of inflammatory cytokines IL-4 and secretory IgA, and improvement of microcirculation in periodontal tissues. Conclusions. The use of drugs increasing insulin sensitivity in the treatment of periodontal diseases in patients with metabolic syndrome can effectively reduce the symptoms of cytokine imbalance, eliminate clinical manifestations of inflammatory reaction in periodontal tissues and lead to long-lasting clinicoradiological remission in the majority of patients.